Candid with the CEO

ADCs

How Lessons from Breast Cancer Are Shaping ADC Development Across Solid Tumors

David Alvaro, Ph.D.

Pharma's Almanac

LNP Analytics

Beyond Particle Size: Building a Complete Analytical Strategy for LNPs

Pharma's Almanac

Viral CDMO

Choosing a CDMO That Can Grow with a Viral Program

Kai Lipinski, Ph.D.

Recipharm Advanced Bio

New Technology

What are the key bottlenecks preventing rapid adoption of novel technologies?

Pharma's Almanac

NAMs

The EMA Builds a Regulatory Safe Harbor for New Approach Methodologies

Pharma's Almanac

Oncolytic Viruses

Turning Oncolytic Viruses into Manufacturable Cancer Therapies

Luisa Amoedo Otero

Recipharm Advanced Bio

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

Biologics Platform

Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Mathias Kahl

IDT Biologika

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biologics

Commercial Thinking Begins in Clinical Phases

Mathias Kahl

IDT Biologika

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics